← All Beigene, LTD filings

Beigene, LTD 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

BGNE
Beigene, LTD
10-K: BeOne Medicines Reports Strong 2025 Revenue Growth, Pipeline Advances
BeOne Medicines Ltd. announced robust financial results for 2025, with total global revenue increasing by 40.2% to $5.3 billion, driven by strong performance of BRUKINSA and TEVIMBRA, alongside significant pipeline advancements and strategic financing.
BGNE
Beigene, LTD
10-K/A: BeiGene Files Amendment to 2024 Annual Report to Include Conformed Signature
BeiGene, Ltd. files an amendment to its 2024 Annual Report on Form 10-K solely to include the conformed signature of the company's current principal accounting officer.
BGNE
Beigene, LTD
10-K: BeiGene Reports Strong 2024 Revenue Growth, Driven by BRUKINSA; Achieves Positive Non-GAAP Operating Income
BeiGene's 2024 results showcase significant revenue growth and progress in hematology and solid tumor pipelines, marking a transition towards sustainable profitability.
BGNE
Beigene, LTD
10-K/A: BeiGene Files Amended 10-K to Include Parent Company Financials
BeiGene, Ltd. has filed an amendment to its annual report to include parent company financial statements due to restricted net assets of subsidiaries exceeding 25% of consolidated net assets.
BGNE
Beigene, LTD
10-K: BeiGene's Share Structure and Corporate Governance Detailed in SEC Filing
BeiGene, Ltd. outlines its share capital, voting rights, and corporate governance in a recent SEC filing, highlighting its global operations and multiple stock listings.